^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Darzalex (daratumumab) (CD38 inhibitor) + pomalidomide (TNFα inhibitor, IL-6 inhibitor, NK cell stimulant, IL-10 stimulant, IL-1β inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs
Published date:
11/06/2019
Excerpt:
Based on these results three patients were able to obtain off-label approval for treatment with Everolimus (for PTEN) (Patient-1) or Trametinib (for KRAS) (Patient 5 & 6) in combination with Pomalidomide (EvoPomDex) w/wo Daratumumab or Tra-PomDex….Patient-6, also presented with EMD, was treated with TraPomDex as the seventh treatment line. TraPomDex treatment was well tolerated, the most significant adverse event diarrhea, infections and pancytopenia. Her biochemical response was a transient VGPR, which was lost during interruption of treatment due to infection. She also died four months after initiation of TraPomDex.
DOI:
https://doi.org/10.1182/blood-2019-127541
